Compare Msci Inc (MSCI) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Msci Inc vs 10X Genomics Inc — how do they compare? Msci Inc trades at $565.48 (market cap $40.38B), while 10X Genomics Inc trades at $81 (market cap $10.07B). The key difference: Msci Inc is far larger — about 4× 10X Genomics Inc's market cap, and Msci Inc pays a 1.48% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Msci Inc for 82 Days and 10X Genomics Inc for 91 Days on average.
| MSCI | TXG | |
|---|---|---|
Market Cap | $40.38B | $10.07B |
Volume | 414,140 | 5,657,286 |
Sector | Financials | Health |
52-Week High | $643.83 | $97.74 |
52-Week Low | $511.84 | $11.48 |
Typical Hold Time | 82 Days | 91 Days |
Enterprise Value | $46.54B | $9.59B |
Dividend Yield | 1.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSCI trades at $563.55, up 1.47% today, with a bullish technical signal and strong fundamentals including 40.73% net income margin and consistent revenue growth. Recent news highlights the completion of the First Street acquisition and upcoming Q3 2026 earnings call, reinforcing its strategic expansion in climate risk analytics.
The outlook is positive with a consensus price target of $701.71, though high valuation ratios and a recent earnings miss pose risks. Long-term growth is supported by recurring revenue streams and market leadership in index and analytics services.
10x Genomics (TXG) trades at $82.37, up 8.24% over 24 hours, with a bearish technical signal and mixed analyst sentiment. The company reported a net loss of $43.54M in 2025, but revenue grew to $642.82M, and it has beaten EPS estimates for three consecutive quarters. Recent news highlights strong demand for its Atera platform and a patent victory, though profitability remains a challenge.
The outlook is cautiously optimistic, with growth potential from new product launches and spatial biology demand, but risks include persistent losses, high valuation multiples, and competitive pressures. The consensus price target is $74.30, below the current price, suggesting limited near-term upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
